Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026
Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study

Fineline Cube Feb 5, 2026
Company Drug

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

Fineline Cube Nov 26, 2024

China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...

Company Deals

E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights

Fineline Cube Nov 26, 2024

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Company

Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results

Fineline Cube Nov 25, 2024

Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...

Policy / Regulatory

National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules

Fineline Cube Nov 25, 2024

The National Allied Procurement Office has released a notification regarding Round 10 of the national...

Policy / Regulatory

Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan

Fineline Cube Nov 25, 2024

China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Thrombus Aspiration Catheter Support Tube

Fineline Cube Nov 25, 2024

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment

Fineline Cube Nov 25, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...

Policy / Regulatory

China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access

Fineline Cube Nov 25, 2024

The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...

Company Drug

MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead

Fineline Cube Nov 25, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Drug

Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies

Fineline Cube Nov 25, 2024

Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...

Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Company Drug

GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan

Fineline Cube Nov 25, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...

Company Drug

China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial

Fineline Cube Nov 25, 2024

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...

Company Drug

J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis

Fineline Cube Nov 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...

Company Drug

Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas

Fineline Cube Nov 25, 2024

French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...

Company Drug

Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer

Fineline Cube Nov 25, 2024

China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...

Company Drug

Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Nov 25, 2024

China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...

Company Deals

Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 25, 2024

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...

Posts pagination

1 … 214 215 216 … 620

Recent updates

  • Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors
  • Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion
  • Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study
  • Takeda Ends $128M Kyoto University iPSC Project After Decade of Research
  • Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Company

Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion

Company Drug

Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.